Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Antengene-ATG

More Like This

PR Newswire associated0

Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

PR Newswire associated0

Antengene Announces 2025 Interim Results with Encouraging Clinical Data and Progress in TCE Platform

PR Newswire associated0

Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025

PR Newswire associated0

Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases

PR Newswire associated0

Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026

Business Wire logo

Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors

AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL

Business Wire logo

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023